Alpine Immune Sciences Future Growth

Future criteria checks 2/6

Alpine Immune SciencesSe prevé que los beneficios de la empresa disminuyan en 25.8% al año, mientras que sus ingresos anuales crecerán en 0.5% al año. Se prevé que el BPA se sitúe en decline a una tasa anual de 15.9%. Se prevé que la rentabilidad de los fondos propios sea de -89.2% en 3 años.

Key information

-12.1%

Earnings growth rate

-9.7%

EPS growth rate

Biotechs earnings growth	20.9%
Revenue growth rate	30.8%
Future return on equity	-117.3%
Analyst coverage	Good
Last updated	21 Mar 2024

Recent future growth updates

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21

Recent updates

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18

We Think The Compensation For Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) CEO Looks About Right

Jun 03

Alpine Immune Sciences files for $150M mixed shelf offering

May 26

Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Mar 29

How Many Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Did Insiders Buy, In The Last Year?

Mar 03

The Alpine Immune Sciences (NASDAQ:ALPN) Share Price Is Up 316% And Shareholders Are Delighted

Feb 05

What Kind Of Shareholders Own Alpine Immune Sciences, Inc. (NASDAQ:ALPN)?

Jan 10

Alpine: Is This A Young Oak Tree?

Jan 05

Does Alpine Immune Sciences (NASDAQ:ALPN) Have A Healthy Balance Sheet?

Dec 15

Earnings and Revenue Growth Forecasts

NasdaqGM:ALPN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	7	-153	-176	-159	6
12/31/2025	19	-112	-140	-118	7
12/31/2024	16	-100	-99	-80	8
12/31/2023	59	-32	-79	-79	N/A
9/30/2023	31	-57	-77	-77	N/A
6/30/2023	29	-59	-78	-77	N/A
3/31/2023	26	-64	-76	-75	N/A
12/31/2022	30	-58	-44	-44	N/A
9/30/2022	32	-54	-42	-42	N/A
6/30/2022	32	-54	4	5	N/A
3/31/2022	34	-47	6	6	N/A
12/31/2021	23	-50	-15	-15	N/A
9/30/2021	25	-42	-10	-10	N/A
6/30/2021	18	-34	-46	-45	N/A
3/31/2021	11	-33	23	24	N/A
12/31/2020	9	-28	29	30	N/A
9/30/2020	5	-28	33	34	N/A
6/30/2020	3	-33	28	29	N/A
3/31/2020	3	-35	-35	-34	N/A
12/31/2019	2	-42	-36	-35	N/A
9/30/2019	1	-47	-39	-39	N/A
6/30/2019	1	-48	-36	-36	N/A
3/31/2019	0	-44	-35	-35	N/A
12/31/2018	1	-36	-29	-28	N/A
9/30/2018	1	-30	-25	-25	N/A
6/30/2018	1	-15	-23	-22	N/A
3/31/2018	1	-11	-19	-19	N/A
12/31/2017	2	-8	-17	-17	N/A
9/30/2017	2	-5	N/A	-13	N/A
6/30/2017	3	-7	N/A	-9	N/A
3/31/2017	3	-3	N/A	-6	N/A
12/31/2016	3	-1	N/A	-4	N/A
12/31/2015	0	0	N/A	5	N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: ALPN se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios frente mercado: ALPN se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: ALPN se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: ALPNSe prevé que los ingresos de la empresa (32.2% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: ALPNSe prevé que los ingresos de la empresa (32.2% al año) crezcan más deprisa que 20% al año.

Earnings per Share Growth Forecasts

Future Return on Equity

Futura rentabilidad financiera (ROE): ALPN se prevé que no sea rentable en 3 años.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Alpine Immune Sciences Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Price target increased by 10% to US$37.00

Price target increased by 9.5% to US$33.57

Price target increased by 11% to US$31.83

Price target increased by 12% to US$30.67

Consensus revenue estimates increase by 12%

Recent updates

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$37.00

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Price target increased by 9.5% to US$33.57

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Price target increased by 11% to US$31.83

Price target increased by 12% to US$30.67

Executive Chairman & CEO exercised options and sold US$1.8m worth of stock

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Executive Chairman & CEO notifies of intention to sell stock

Consensus revenue estimates increase by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New minor risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Consensus revenue estimates fall by 33%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Price target decreased to US$18.33

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Consensus EPS estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Alpine: Rest Before Rallying Again

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insider recently sold US$237k worth of stock

Insufficient new directors

Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in funding from Horizon Therapeutics Public Limited Company

Insufficient new directors

Third quarter 2021 earnings released: US$0.55 loss per share (vs US$0.28 loss in 3Q 2020)

Independent Director recently bought US$98k worth of stock

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Price target decreased to US$20.00

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.53 loss in 2Q 2020)